You are seeing this message because your Web browser does not support basic Web standards. Find out more about why this message is appearing and what you can do to make your experience on this site better.


ABOUT ARCHIVES
Advanced Search

Welcome   | My Account | E-mail Alerts | Access Rights | Sign In


  Vol. 65 No. 1, January 2008 TABLE OF CONTENTS
  Archives
  •  Online Features
  Observation
 This Article
 •Full text
 •PDF
 • Reply to article
 •Send to a friend
 • Save in My Folder
 •Save to citation manager
 •Permissions
 Citing Articles
 •Citation map
 •Contact me when this article is cited
 Related Content
 •Similar articles in this journal
 Topic Collections
 •Genetic Disorders
 •Neurogenetics
 •Neuromuscular diseases
 •Neurology, Other
 •Alert me on articles by topic

Mild POMGnT1 Mutations Underlie a Novel Limb-Girdle Muscular Dystrophy Variant

Emma M. Clement, MB, ChB; Caroline Godfrey, BSc; Jenny Tan, PhD; Martin Brockington, BSc; Silvia Torelli, PhD; Lucy Feng, PhD; Susan C. Brown, PhD; Cecilia Jimenez-Mallebrera, PhD; Caroline A. Sewry, PhD; Cheryl Longman, MD; Rachael Mein, BSc; Steve Abbs, PhD; Jiri Vajsar, MD; Harry Schachter, MD, PhD; Francesco Muntoni, MD

Arch Neurol. 2008;65(1):137-141.

Background  Mutations in protein-O-mannose-β1,2-N-acetylglucosaminyltransferase 1 (POMGnT1) have been found in muscle-eye-brain disease, a congenital muscular dystrophy with structural eye and brain defects and severe mental retardation.

Objective  To investigate whether mutations in POMGnT1 could be responsible for milder allelic variants of muscular dystrophy.

Design  Screening for mutations in POMGnT1.

Setting  Tertiary neuromuscular unit.

Patient  A patient with limb-girdle muscular dystrophy phenotype, with onset at 12 years of age, severe myopia, normal intellect, and decreased {alpha}-dystroglycan immunolabeling in skeletal muscle.

Results  A homozygous POMGnT1 missense mutation (c.1666G>A, p.Asp556Asn) was identified. Enzyme studies of the patient's fibroblasts showed an altered kinetic profile, less marked than in patients with muscle-eye-brain disease and in keeping with the relatively mild phenotype in our patient.

Conclusions  Our findings widen the spectrum of disorders known to result from mutations in POMGnT1 to include limb-girdle muscular dystrophy with no mental retardation. We propose that this condition be known as LGMD2M. The enzyme assay used to diagnose muscle-eye-brain disease may not detect subtle abnormalities of POMGnT1 function, and additional kinetic studies must be carried out in such cases.


Author Affiliations: Dubowitz Neuromuscular Unit, Department of Paediatrics, Hammersmith Hospital, Imperial College London (Drs Clement, Torelli, Feng, Brown, Jimenez-Mallebrera, Sewry, Longman, and Muntoni), Ms Godfrey, Mr Brockington, and DNA Laboratory, Genetics Centre, Guy's Hospital (Mss Godfrey and Mein and Dr Abbs), London, and Centre for Inherited Neuromuscular Disorders, Robert Jones and Agnes Hunt Orthopaedic Hospital, Oswestry (Dr Sewry), England; and Department of Structural Biology and Biochemistry (Drs Tan and Schachter) and Division of Neurology (Dr Vajsar), Hospital for Sick Children, and Faculty of Medicine, University of Toronto (Drs Vajsar and Schachter), Toronto, Ontario, Canada.







HOME | CURRENT ISSUE | PAST ISSUES | TOPIC COLLECTIONS | CME | SUBMIT | SUBSCRIBE | HELP
CONDITIONS OF USE | PRIVACY POLICY | CONTACT US | SITE MAP
 
© 2008 American Medical Association. All Rights Reserved.